ESR1 and breast carcinoma: Therefore, we were surprised to find that high levels of TEAD4 correlated with poor prognosis in ER+ breast cancer patients (Fig. 5a), which is in contrast to YAP (Fig. 1b), implying that TEAD may promote ER+ breast cancer progression.